ArticleJTCVS open2026
Surgical therapy for pulmonary aspergillomas and mucormycosis: A 15-year experience from a single clinical center.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The aim of this study was to evaluate the efficacy of surgical treatment for pulmonary aspergillomas and mucormycosis. Methods: A retrospective review was conducted of 97 patients underwent surgical resection for pulmonary aspergillomas and mucormycosis at a tertiary center in China from 2010 to 2024. Results: This study enrolled 23 patients with pulmonary mucormycosis and 74 patients with pulmonary aspergillomas. The average age of patients diagnosed with aspergillomas was significantly lower than that of patients diagnosed with mucormycosis (35.4 ± 15.8 vs 51.5 ± 12.7, Conclusions: Compared with pulmonary aspergillomas, pulmonary mucormycosis demonstrates greater aggressiveness, affects patients at a younger age, and necessitates more extensive lung resection. In addition, the long-term survival after surgery for pulmonary mucormycosis is poorer compared with that for aspergillomas.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.